Abstract
Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.
Original language | English (US) |
---|---|
Pages (from-to) | S19-S27 |
Journal | European Journal of Nuclear Medicine and Molecular Imaging |
Volume | 30 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - Jun 1 2003 |
Externally published | Yes |
Keywords
- Early-stage disease
- Hodgkin's disease
- Long-term toxicity
- Treatment
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging